Figure 2.

Effects of PART‐1 on the cell viability and apoptosis of chondrocytes. A‐E, Chondrocytes were transfected with PART‐1 siRNAs (si‐PART‐1(a) or (b)) or the scrambled negative controls; at 24 h after transfection, (A) the PART‐1 expression was analysed by qRT‐PCR; at 0, 24, 48 and 72 h after transfection, (B) cell viability was determined by CCK‐8 assay; at 24 h after transfection, (C) caspase‐3 activity was measured by the caspase‐3 activity kit, (D) cell apoptotic rates were analysed by flow cytometry; (E) protein levels were determined by Western blot assay. (F) Cells were transfected with pcDNA3.1‐PART‐1 or pcDNA3.1; at 24 h after transfection, the PART‐1 expression was determined by qRT‐PCR assay. (G) Cells were treated with IL‐1β for 24 h, and the PART‐1 expression was determined by qRT‐PCR assay. H‐K, Cells with IL‐1β treatment were transfected pcDNA3.1 or pcDNA3.1‐PART‐1, and at 0, 24, 48 and 72 h after transfection, (H) cell viability was determined by CCK‐8 assay; at 24 h after transfection, (I) caspase‐3 activity was measured by the caspase‐3 activity kit, (J) cell apoptotic rates were analysed by flow cytometry; (K) protein levels were determined by Western blot assay. N = 3; significant differences were presented as *P < .05, **P < .01 and ***P < .001